Whole body imaging of luciferase activity in vivo was monitored using an In Vivo MS FX PRO imaging system (Bruker, Billerica, MA). Male and female mice were injected IP with 150 mg/kg body weight of d;-luciferin solution (Promega, Madison, WI) and anesthetized (2.5% isoflurane). Mice were transferred to nose cones within the chamber and imaged 10 minutes after injection of D-luciferin. Exposure time was 10 seconds on the ventral side, and luminescence was quantified using the Bruker imaging software. Bright-field images were also taken of mice with an exposure time of 5 seconds. Tissues, collected from male mice, were also imaged using the In Vivo MS FX PRO. Briefly, male mice were injected IP with 150 mg/kg body weight of D-luciferin solution and dissected 10 minutes later. Tissues were placed in chamber and bright-field, and luminescence images were taken using the same exposure times for in vivo imaging.
D luciferin solution
Manufactured by Promega
Sourced in United States
D-luciferin solution is a chemiluminescent compound commonly used in bioluminescence applications. It serves as a substrate for firefly luciferase, an enzyme that catalyzes the oxidation of luciferin to produce light. The solution is a standard component in various biochemical and molecular biology assays.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using d luciferin solution
1
Whole-Body In Vivo Luciferase Imaging
2
Tumor Xenograft Model for Drug Response
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To investigate local tumor invasion and drug response, we used non-obese diabetic (NOD)/severe-combined immunodeficient (SCID) mice from BioLASCO (Taiwan) to establish mouse tumor xenografts by subcutaneously injecting cancer cells (2 × 106 cells in 100 μl PBS) expressing luciferase 2 into the legs of 7 week-old male NOD/SCID mice. For the drug response experiments, AZD0530 (LC Laboratories) was dissolved in DMSO to generate a concentration of 200 mg/ml and diluted in 0.2% Tween 80 /PBS before administration. When tumors reached a size of ~50 mm3, mice were treated with either vehicle (DMSO in 0.2% Tween 80/PBS) or 30 mg/kg AZD0530 by oral gavage once a day for 6 consecutive days with one day of rest for a period of 4 weeks. Tumor progression was monitored once a week with an in vivo imaging system (IVIS). Briefly, mice were anesthetized with isoflurane gas and injected intraperitoneally (150 mg/kg) with D-luciferin solution (Promega) and bioluminescent image measurements obtained using an IVIS Spectrum (Xenogen IVIS 100; Caliper). Mice were maintained under specific pathogen-free conditions at the Laboratory Animal Center of Chang-Gung University (Taoyuan, Taiwan). All animal experiments were handled according to the accepted principles of laboratory animal care and approved by the animal committee of Chang-Gung University and National Central University (Taoyuan, Taiwan).
3
In Vivo Tumor Imaging in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
LLC/Fluc cells (3.0 × 105) were subcutaneously injected into the hindlimb of 6-11-week-old B6 albino mice with or without of MLACs, Mo-MDSCs, or PMN-MDSCs (4.0 × 105 cells each). Tumor-bearing mice were intraperitoneally injected with 150 μl of 100 μg/ml D-luciferin solution (Promega) and imaged at 20 min post-injection in an in vivo photoncounting device IVIS®-spectrum (Perkin Elmer, Illinois, USA). The following conditions were used for image acquisition: exposure time = 2 min, binning = medium: 8, field of view = 22.5 × 22.5 cm, and f/stop = 1. The minimum and maximum photons/s/cm2/sr of each image is indicated in each Figure by a rainbow bar scale.
4
Tumor Growth Dynamics Monitoring
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Luminescence and volumetric measurements were used to assess the growth dynamics of tumours. After PEF treatment, the volume of tumours (or forming scabs) was determined by measuring centered tumour length and width with a digital caliper every 2–3 days after the treatment. The volumes of tumours (mm3) were calculated by the formula: V = (Length × Width2 × π)/6, where π = 3.1416. When the tumour volume reached about 3000 mm3, the mice were sacrificed by cervical dislocation.
The luminescence of tumours was assessed by imaging tumours with IVIS Spectrum equipment and Living Image Software (Caliper/Perkin Elmer, Akron, OH, USA). Prior to the treatment, mice were intraperitoneally injected with 150 µL (30 mg/mL in PBS) of D-luciferin solution (Promega, Madison, WI, USA). After 10–15 min, mice were visualised under anaesthesia with 3% isoflurane and oxygen gas mixture that was later lowered to 1.5% (Vetpharma Animal Health, S.L., Barcelona, Spain). Then, tumours were imaged before the treatment, right after the bleomycin and PEF treatment, as well as 11 days after the treatment. The bioluminescence of tumours was proportional to the number of live LLC1-Luc cells. Luminescence was expressed as the photons/sec/region of interest (ROI) by subtracting the background luminescence of the same size region.
The luminescence of tumours was assessed by imaging tumours with IVIS Spectrum equipment and Living Image Software (Caliper/Perkin Elmer, Akron, OH, USA). Prior to the treatment, mice were intraperitoneally injected with 150 µL (30 mg/mL in PBS) of D-luciferin solution (Promega, Madison, WI, USA). After 10–15 min, mice were visualised under anaesthesia with 3% isoflurane and oxygen gas mixture that was later lowered to 1.5% (Vetpharma Animal Health, S.L., Barcelona, Spain). Then, tumours were imaged before the treatment, right after the bleomycin and PEF treatment, as well as 11 days after the treatment. The bioluminescence of tumours was proportional to the number of live LLC1-Luc cells. Luminescence was expressed as the photons/sec/region of interest (ROI) by subtracting the background luminescence of the same size region.
5
In Vivo Bioluminescence Imaging of Tumor Xenografts
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice with E0771/mKO2-luc2 and 4T1/Fluc tumors were intraperitoneally injected with 100 µl of 100 µg/ml D-luciferin solution (Promega) and sequentially imaged every 3 min for 21 min using an in vivo photon-counting device IVIS®-spectrum, and images with the maximum photon counts were used for analysis. The following conditions were used for image acquisition: exposure time = 1 min, binning = medium: 8, field of view = 22.5 × 22.5 cm, and f/stop = 1. The minimum and maximum photon/second/cm2/steradian (p/s/cm2/sr) for each image are indicated in each figure by a rainbow bar scale.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!